Age, Biography and Wiki
Tomáš Cihlář was born on 1967 in Plzeň, Czechoslovakia (now Czech Republic). Discover Tomáš Cihlář's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 56 years old?
Popular As |
N/A |
Occupation |
Biochemist, virologist |
Age |
56 years old |
Zodiac Sign |
|
Born |
1967 |
Birthday |
1967 |
Birthplace |
Plzeň, Czechoslovakia (now Czech Republic) |
Nationality |
Slovakia |
We recommend you to check the complete list of Famous People born on 1967.
He is a member of famous with the age 56 years old group.
Tomáš Cihlář Height, Weight & Measurements
At 56 years old, Tomáš Cihlář height not available right now. We will update Tomáš Cihlář's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
Physical Status |
Height |
Not Available |
Weight |
Not Available |
Body Measurements |
Not Available |
Eye Color |
Not Available |
Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
Family |
Parents |
Not Available |
Wife |
Not Available |
Sibling |
Not Available |
Children |
Not Available |
Tomáš Cihlář Net Worth
His net worth has been growing significantly in 2022-2023. So, how much is Tomáš Cihlář worth at the age of 56 years old? Tomáš Cihlář’s income source is mostly from being a successful . He is from Slovakia. We have estimated
Tomáš Cihlář's net worth
, money, salary, income, and assets.
Net Worth in 2023 |
$1 Million - $5 Million |
Salary in 2023 |
Under Review |
Net Worth in 2022 |
Pending |
Salary in 2022 |
Under Review |
House |
Not Available |
Cars |
Not Available |
Source of Income |
|
Tomáš Cihlář Social Network
Instagram |
|
Linkedin |
|
Twitter |
|
Facebook |
|
Wikipedia |
|
Imdb |
|
Timeline
In April 2021 Cihlář discussed the possibility of marketing remdesivir in pill form.
At Gilead, leading a team of hundreds of scientists working on new substances for the treatment of HIV, viral hepatitis B, respiratory infections and other viral diseases such as Ebola, MERS, and dengue fever, Cihlář is as of 2020 responsible for biological research on HIV and respiratory viruses. On a number of these projects, he continues to work closely with scientists from the Institute of Organic Chemistry and Biochemistry, particularly Zdeněk Havlas and Zdeněk Hostomský, and with the Radim Nencka Group, which develops compounds capable of stopping the replication of important human pathogens by blocking the remodeling of cell membranes induced by these viruses.
Also at Gilead, Cihlář is one of the company's lead researchers in the development of remdesivir, originally intended for treatment of Ebola. However, the Ebola epidemic ended before the new drug could be tested. Remdesivir briefly showed considerable promise in treating COVID-19 infection; in April 2020 the company provided 5,000 doses for experimental use in China and four hundred patients in 50 other countries. Remdesivir was used to treat the first confirmed case of coronavirus in the U.S.
In early June 2020 it was reported that AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company headquartered in Cambridge, England, was pursuing a merger with Gilead due to a shared interest in the potential of remdesivir.
In September 2020, following a review of purported evidence, the WHO’s guidelines committee issued a statement that there was no evidence of benefit, adding that Covid patients may be better off without it. The statement, published in The BMJ, concludes, "Any beneficial effects of remdesivir, if they do exist, are likely to be small and the possibility of important harm remains.” In October 2020, recognizing his involvement in the development of Remdesivir, which was thought potentially effective in treating Covid-19, Czech president Miloš Zeman awarded Cihlář the country's Silver Medal of Merit.
In 2006, Cihlář received a William Prusoff Young Investigator Lecture Award from the International Society for Antiviral Research for his work on antiviral nucleotide analogs. He has patented dozens of novel inventions.
Cihlář graduated from the University of Chemistry and Technology, Prague, majoring in fermentation chemistry and bioengineering under the tutelage of Jan Páca and Vladimír Jirků. He completed his postgraduate studies at the Institute of Organic Chemistry and Biochemistry of the ASCR under Ivan Rosenberg and Ivan Votruba. In 1994 he obtained the title of Candidate of Sciences and was engaged in the research of antiviral agents under the tutelage of Antonín Holý.
Tomáš Cihlář (born 1967) is a Czech biochemist known for his role in the development of remdesivir. A specialist in virology, Cihlář holds the positions of Senior Director, Biology, and Vice-President at American pharmaceutical company Gilead Sciences. As a student, Cihlář assisted fellow biochemist Antonín Holý in developing Viread, the primary drug used to fight HIV infection.